Exactly.
So instead of just talking up the PRV, how about including more upfront info. Such as:
The RPDD is welcome recognition from the FDA. While a PRV would provide considerable value to the company, we have every intention to continue to rapidly advance RC220 in our lead indications. As such we expect that the award of a PRV unlikely due to seeking FDA approval in other indications before paediac AML.
Ann: FDA RPD Designation Granted for RC220 Bisantrene, page-30
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
